<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03791905</url>
  </required_header>
  <id_info>
    <org_study_id>PETESCC</org_study_id>
    <nct_id>NCT03791905</nct_id>
  </id_info>
  <brief_title>PET Imaging-guided Chemoradiotherapy in Esophageal Squamous Cell Carcinoma</brief_title>
  <official_title>A Phase II Randomized Trial of PET Imaging in Assessing Response to Induction Chemotherapy in Esophageal Squamous Cell Carcinoma Treated With Definitive Chemoradiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mian XI</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Since multiple studies have demonstrated that PET can identify responders and non-responders&#xD;
      to induction chemotherapy, using FDG-PET imaging to guide treatment decisions has prompted&#xD;
      interest in clinical practice. The aim of this study was to evaluate whether changing&#xD;
      chemotherapy regimen during radiation based on PET response to induction chemotherapy can&#xD;
      improve clinical complete response (cCR) in patients with unresectable esophageal squamous&#xD;
      cell carcinoma (ESCC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 216 patients with baseline PET scan were randomized to one of 2 induction&#xD;
      chemotherapy arms: paclitaxel/cisplatin (TP) on days 1, 22 or FOLFOX (oxaliplatin,&#xD;
      leucovorin, 5-FU) on days 1, 15, 29. Repeat PET was performed on days 36-42 and changes in&#xD;
      max standardized uptake value (SUVmax) from baseline were assessed. Using a predefined&#xD;
      cut-off value of a 35% decrease in SUVmax, PET responders (≥35% decrease in SUVmax) continued&#xD;
      on the same chemotherapy regimen during radiotherapy, whereas PET non-responders (&lt;35%&#xD;
      decrease in SUVmax) crossed over to an alternative chemotherapy regimen concomitantly with&#xD;
      radiation. All patients received external-beam radiation using intensity-modulated&#xD;
      radiotherapy. The prescribed dose is generally 50-60 Gy in 25-28 fractions, 5 days per week.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2019</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized parallel study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>clinical complete response</measure>
    <time_frame>3 months after the treatment (plus or minus 7 days)</time_frame>
    <description>RECIST (Response Evaluation Criteria in Solid Tumors) criteria was used to determine the tumor response. Tumor response was evaluated 3 months after the completion of treatment based on CT or PET-CT scans, endoscopy with biopsies.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years after randomization</time_frame>
    <description>From the enrollment to the date of death from any cause or date of lost follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>3 years after randomization</time_frame>
    <description>From the date of randomization to the date of disease progression or last follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chemoradiotherapy-related toxicity</measure>
    <time_frame>From the date of randomization to the 3 months after treatment</time_frame>
    <description>Treatment-related toxicity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">216</enrollment>
  <condition>Neoplasm, Esophageal</condition>
  <condition>Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>TP Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with baseline PET scan assigned to this Arm will receive two cycles of 3-weekly schedule of induction chemotherapy with paclitaxel/cisplatin (TP), consisting of paclitaxel 150 mg/m2 on day 1 and cisplatin 75 mg/m2 on day 1. Repeat PET was performed on days 36-42 and changes in SUVmax from baseline were assessed. PET responders (≥35% decrease in SUVmax) continued on the same chemotherapy regimen during radiotherapy, whereas PET non-responders (&lt;35% decrease in SUVmax) crossed over to FOLFOX regimen concomitantly with radiation. All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is generally 50-60 Gy in 25-28 fractions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FOLFOX Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with baseline PET scan assigned to this Arm will receive three cycles of 2-weekly schedule of induction chemotherapy with FOLFOX (oxaliplatin, leucovorin, 5-FU), consisting of oxaliplatin 85 mg/m2 on day 1, leucovorin 400 mg/m2, and 5-FU 2 g/m2 on day 1. Repeat PET was performed on days 36-42 and changes in SUVmax from baseline were assessed. PET responders (≥35% decrease in SUVmax) continued on the same chemotherapy regimen during radiotherapy, whereas PET non-responders (&lt;35% decrease in SUVmax) crossed over to TP regimen concomitantly with radiation. All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is generally 50-60 Gy in 25-28 fractions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>chemotherapy drug</description>
    <arm_group_label>TP Arm</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>chemotherapy drug</description>
    <arm_group_label>TP Arm</arm_group_label>
    <other_name>DDP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>chemotherapy drug</description>
    <arm_group_label>FOLFOX Arm</arm_group_label>
    <other_name>OXA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <description>chemotherapy drug</description>
    <arm_group_label>FOLFOX Arm</arm_group_label>
    <other_name>Fluorouracil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <description>chemotherapy drug</description>
    <arm_group_label>FOLFOX Arm</arm_group_label>
    <other_name>CF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intensity-modulated radiotherapy</intervention_name>
    <description>radiotherapy technique</description>
    <arm_group_label>FOLFOX Arm</arm_group_label>
    <arm_group_label>TP Arm</arm_group_label>
    <other_name>IMRT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PET</intervention_name>
    <description>Using PET to evaluate response to induction chemotherapy</description>
    <arm_group_label>FOLFOX Arm</arm_group_label>
    <arm_group_label>TP Arm</arm_group_label>
    <other_name>PET-CT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed squamous cell carcinoma of the esophagus;&#xD;
&#xD;
          2. Absence of hematogenous metastasis disease, confirmed by endoscopic ultrasound (EUS)&#xD;
             and PET-CT scan (according to UICC TNM version 8);&#xD;
&#xD;
          3. Not suitable for surgery (either for medical reasons or patient's choice);&#xD;
&#xD;
          4. Age at diagnosis 18 to 70 years;&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group performance status ≤ 2&#xD;
&#xD;
          6. No prior cancer therapy;&#xD;
&#xD;
          7. No history of concomitant or previous malignancy;&#xD;
&#xD;
          8. Hematologic function: WBC ≥ 4.0×109/L, PLT ≥ 80×109/L, Hb ≥ 10mg/dL;&#xD;
&#xD;
          9. Renal function: Cr ≤ 1.25×UNL;&#xD;
&#xD;
         10. Hepatic function: BIL ≤ 1.5×UNL, ALT/AST ≤ 2.5×UNL;&#xD;
&#xD;
         11. Documented informed consent to participate in the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Younger than 18 or older than 70 years of age;&#xD;
&#xD;
          2. ECOG performance status of 3 or above;&#xD;
&#xD;
          3. Other cancer history;&#xD;
&#xD;
          4. Previous radiotherapy history;&#xD;
&#xD;
          5. Subjects with distant metastases;&#xD;
&#xD;
          6. Pregnancy or breast feeding. Women of childbearing age must use effective&#xD;
             contraception;&#xD;
&#xD;
          7. Serious cardiovascular disease (congestive heart failure, uncontrollable arrhythmia,&#xD;
             unstable angina, myocardial infarction, serious heart valve disease, resistant&#xD;
             hypertension);&#xD;
&#xD;
          8. Evidence of bleeding diathesis or serious infection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mian XI, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mian XI, MD</last_name>
    <phone>+86-20-87343385</phone>
    <email>ximian@sysucc.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mengzhong Liu, MD</last_name>
    <phone>+86-20-87343385</phone>
    <email>liumzh@sysucc.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guanzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mian Xi, MD</last_name>
      <phone>+86-20-87343385</phone>
      <email>ximian@sysucc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Ku GY, Kriplani A, Janjigian YY, Kelsen DP, Rusch VW, Bains M, Chou J, Capanu M, Wu AJ, Goodman KA, Ilson DH. Change in chemotherapy during concurrent radiation followed by surgery after a suboptimal positron emission tomography response to induction chemotherapy improves outcomes for locally advanced esophageal adenocarcinoma. Cancer. 2016 Jul 1;122(13):2083-90. doi: 10.1002/cncr.30028. Epub 2016 May 6.</citation>
    <PMID>27152857</PMID>
  </results_reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 31, 2018</study_first_submitted>
  <study_first_submitted_qc>December 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 3, 2019</study_first_posted>
  <last_update_submitted>March 21, 2021</last_update_submitted>
  <last_update_submitted_qc>March 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Mian XI</investigator_full_name>
    <investigator_title>Associate Preofessor</investigator_title>
  </responsible_party>
  <keyword>Esophageal squamous cell carcinoma</keyword>
  <keyword>PET</keyword>
  <keyword>Definitive chemoradiotherapy</keyword>
  <keyword>Induction chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

